|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
CA2555185C
(en)
|
2004-02-06 |
2020-03-24 |
Morphosys Ag |
Anti-cd38 human antibodies and uses therefor
|
|
JP2008504013A
(ja)
|
2004-02-06 |
2008-02-14 |
モルフォシス・アクチェンゲゼルシャフト |
抗ｃｄ３８ヒト抗体及びその用途
|
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
|
JP5362359B2
(ja)
|
2005-10-12 |
2013-12-11 |
モルフォシス アーゲー |
ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
|
|
AU2006330411B2
(en)
|
2005-12-29 |
2012-07-12 |
Janssen Biotech, Inc. |
Human anti-IL-23 antibodies, compositions, methods and uses
|
|
WO2007142241A1
(ja)
*
|
2006-06-05 |
2007-12-13 |
Hiroshima University |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
HRP20191115T1
(hr)
|
2006-09-26 |
2019-09-20 |
Genmab A/S |
Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
|
|
AU2013209322A1
(en)
*
|
2006-10-19 |
2013-08-15 |
Sanofi-Aventis |
Novel anti-cd38 antibodies for the treatment of cancer
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
EP2191841A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
LT2621531T
(lt)
|
2010-09-27 |
2017-04-10 |
Morphosys Ag |
Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
|
|
KR20130066682A
(ko)
*
|
2010-10-05 |
2013-06-20 |
다이이찌 산쿄 가부시키가이샤 |
항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
HUE036518T2
(hu)
|
2012-09-25 |
2018-07-30 |
Morphosys Ag |
Kombinációk és alkalmazásaik
|
|
DK2914302T3
(en)
|
2012-11-05 |
2017-04-10 |
Morphosys Ag |
RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
|
|
JP2014117191A
(ja)
*
|
2012-12-13 |
2014-06-30 |
Fisheries Research Agency |
リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
ES2774976T3
(es)
*
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
BR112016009919A2
(pt)
|
2013-11-04 |
2017-12-05 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
EP3954713A3
(en)
*
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
WO2015195555A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
US10106620B2
(en)
|
2014-06-16 |
2018-10-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
|
|
MY192918A
(en)
|
2014-09-09 |
2022-09-15 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
US10532106B2
(en)
|
2014-10-29 |
2020-01-14 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for MT1-MMP
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
EP3227338A4
(en)
|
2014-12-04 |
2018-05-16 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
|
WO2016164656A1
(en)
*
|
2015-04-08 |
2016-10-13 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd38
|
|
HRP20210552T1
(hr)
|
2015-05-13 |
2021-05-14 |
Morphosys Ag |
Liječenje multiplog mijeloma (mm)
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
|
MY192978A
(en)
|
2015-06-22 |
2022-09-20 |
Janssen Biotech Inc |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
HUE066300T2
(hu)
|
2015-06-24 |
2024-07-28 |
Janssen Biotech Inc |
Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
|
|
PL3827845T3
(pl)
|
2015-11-03 |
2022-07-11 |
Janssen Biotech, Inc. |
Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
AU2017226960B2
(en)
|
2016-03-04 |
2024-03-21 |
Morphosys Ag |
Clinical assessment of M-protein response in multiple myeloma
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
EP3487506A1
(en)
|
2016-07-20 |
2019-05-29 |
Hybrigenics SA |
Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
|
|
JP7679196B2
(ja)
*
|
2017-06-08 |
2025-05-19 |
ブラック ベルト セラピューティクス リミテッド |
Ｃｄ３８調節抗体
|
|
CN110997722B
(zh)
|
2017-06-08 |
2023-09-26 |
黑带医疗有限公司 |
Cd38调节抗体
|
|
JP7359700B2
(ja)
|
2017-06-20 |
2023-10-11 |
ソレント・セラピューティクス・インコーポレイテッド |
Ｃｄ３８抗体薬物コンジュゲート
|
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
CA3072296A1
(en)
|
2017-08-16 |
2019-02-21 |
Black Belt Therapeutics Limited |
Cd38 antibody
|
|
CN111032693B
(zh)
|
2017-08-16 |
2023-09-26 |
黑带医疗有限公司 |
Cd38调节抗体
|
|
US11542338B2
(en)
|
2017-08-16 |
2023-01-03 |
Black Belt Therapeutics Limited |
CD38 modulating antibody
|
|
JP7036909B2
(ja)
*
|
2017-10-10 |
2022-03-15 |
サノフイ |
抗ｃｄ３８抗体および使用方法
|
|
CA3079242A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US20230158070A1
(en)
|
2018-01-30 |
2023-05-25 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
CN110144008B
(zh)
*
|
2018-02-12 |
2021-03-19 |
杭州尚健生物技术有限公司 |
Cd38蛋白抗体及其应用
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
GB201810320D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to CD38
|
|
JP2022512722A
(ja)
|
2018-10-17 |
2022-02-07 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体の皮下投与を提供する方法
|
|
BR112021009287A2
(pt)
|
2018-11-20 |
2021-10-26 |
Janssen Biotech, Inc. |
Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
EP3893841A1
(en)
|
2018-12-14 |
2021-10-20 |
MorphoSys AG |
Antibody formulations
|
|
WO2020128526A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicycletx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
GB201900530D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for CD38
|
|
WO2020187718A1
(en)
|
2019-03-15 |
2020-09-24 |
Morphosys Ag |
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
|
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
AU2020307667A1
(en)
|
2019-06-27 |
2022-01-20 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
|
|
US20220257796A1
(en)
|
2019-07-02 |
2022-08-18 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
TWI862640B
(zh)
|
2019-07-30 |
2024-11-21 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
EP4130035A4
(en)
*
|
2020-03-31 |
2024-06-26 |
Bio-Thera Solutions, Ltd. |
Antibody and fusion protein for treating coronaviruses and use thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4596046A3
(en)
|
2020-05-21 |
2025-10-22 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
EP4171585A1
(en)
|
2020-06-26 |
2023-05-03 |
CRISPR Therapeutics AG |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
CN114075283A
(zh)
*
|
2020-08-12 |
2022-02-22 |
三生国健药业（上海）股份有限公司 |
结合人cd38的抗体、其制备方法和用途
|
|
CN114195893A
(zh)
*
|
2020-09-17 |
2022-03-18 |
百奥泰生物制药股份有限公司 |
抗整联蛋白抗体或抗原结合片段及其应用
|
|
GB202016331D0
(en)
|
2020-10-15 |
2020-12-02 |
Bicyclerd Ltd |
Bicyclic peptide ligand drug conjugates
|
|
US20220202859A1
(en)
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
|
|
JP2024503432A
(ja)
|
2021-01-14 |
2024-01-25 |
モルフォシス・アーゲー |
抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
US20220387488A1
(en)
|
2021-05-12 |
2022-12-08 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
|
|
US20220378829A1
(en)
|
2021-05-12 |
2022-12-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating solid tumors
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|
|
MX2024005406A
(es)
|
2021-11-03 |
2024-08-06 |
Janssen Biotech Inc |
Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
|
|
WO2023098813A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Nanjing Leads Biolabs Co., Ltd. |
Antibodies binding cd38 and uses thereof
|
|
EP4472740A1
(en)
|
2022-01-31 |
2024-12-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|